RUNX1	O
DNA	O
-	O
binding	O
mutations	O
and	O
RUNX1	O
-	O
PRDM16	O
cryptic	O
fusions	O
in	O
BCR	B-Cancer
-	I-Cancer
ABL	I-Cancer
+	I-Cancer
leukemias	I-Cancer
are	O
frequently	O
associated	O
with	O
secondary	O
trisomy	O
21	B-Cellular_component
and	O
may	O
contribute	O
to	O
clonal	B-Cell
evolution	O
and	O
imatinib	O
resistance	O
.	O

Acquired	O
molecular	O
abnormalities	O
(	O
mutations	O
or	O
chromosomal	B-Cellular_component
translocations	O
)	O
of	O
the	O
RUNX1	O
transcription	O
factor	O
gene	O
are	O
frequent	O
in	O
acute	B-Cancer
myeloblastic	I-Cancer
leukemias	I-Cancer
(	O
AMLs	B-Cancer
)	O
and	O
in	O
therapy	O
-	O
related	O
myelodysplastic	O
syndromes	O
,	O
but	O
rarely	O
in	O
acute	B-Cancer
lymphoblastic	I-Cancer
leukemias	I-Cancer
(	O
ALLs	B-Cancer
)	O
and	O
chronic	B-Cancer
myelogenous	I-Cancer
leukemias	I-Cancer
(	O
CMLs	B-Cancer
)	O
.	O

Among	O
18	O
BCR	B-Cancer
-	I-Cancer
ABL	I-Cancer
+	I-Cancer
leukemias	I-Cancer
presenting	O
acquired	O
trisomy	O
of	O
chromosome	B-Cellular_component
21	I-Cellular_component
,	O
we	O
report	O
a	O
high	O
frequency	O
(	O
33	O
%	O
)	O
of	O
recurrent	O
point	O
mutations	O
(	O
4	O
in	O
myeloid	B-Cancer
blast	I-Cancer
crisis	I-Cancer
[	I-Cancer
BC	I-Cancer
]	I-Cancer
CML	I-Cancer
and	O
one	O
in	O
chronic	B-Cancer
phase	I-Cancer
CML	I-Cancer
)	O
within	O
the	O
DNA	O
-	O
binding	O
region	O
of	O
RUNX1	O
.	O

We	O
did	O
not	O
found	O
any	O
mutation	O
in	O
de	O
novo	O
BCR	B-Cancer
-	I-Cancer
ABL	I-Cancer
+	I-Cancer
ALLs	I-Cancer
or	O
lymphoid	B-Cancer
BC	I-Cancer
CML	I-Cancer
.	O

Emergence	O
of	O
the	O
RUNX1	O
mutations	O
was	O
detected	O
at	O
diagnosis	O
or	O
before	O
the	O
acquisition	O
of	O
trisomy	O
21	B-Cellular_component
during	O
disease	O
progression	O
.	O

In	O
addition	O
,	O
we	O
also	O
report	O
a	O
high	O
frequency	O
of	O
cryptic	O
chromosomal	B-Cellular_component
RUNX1	O
translocation	O
to	O
a	O
novel	O
recently	O
described	O
gene	O
partner	O
,	O
PRDM16	O
on	O
chromosome	B-Cellular_component
1p36	I-Cellular_component
,	O
for	O
3	O
(	O
21	O
.	O
4	O
%	O
)	O
of	O
14	O
investigated	O
patients	O
:	O
2	O
myeloid	B-Cancer
BC	I-Cancer
CMLs	I-Cancer
and	O
,	O
for	O
the	O
first	O
time	O
,	O
1	O
therapy	O
-	O
related	O
BCR	B-Cancer
-	I-Cancer
ABL	I-Cancer
+	I-Cancer
ALL	I-Cancer
.	O

Two	O
patients	O
presented	O
both	O
RUNX1	O
mutations	O
and	O
RUNX1	O
-	O
PRDM16	O
fusion	O
.	O

These	O
events	O
are	O
associated	O
with	O
a	O
short	O
survival	O
and	O
support	O
the	O
concept	O
of	O
a	O
cooperative	O
effect	O
of	O
BCR	O
-	O
ABL	O
with	O
molecular	O
RUNX1	O
abnormalities	O
on	O
the	O
differentiation	O
arrest	O
phenotype	O
observed	O
during	O
progression	O
of	O
CML	B-Cancer
and	O
in	O
BCR	B-Cancer
-	I-Cancer
ABL	I-Cancer
+	I-Cancer
ALL	I-Cancer
.	O

